GLP-1 Peptides

GLP-1 peptides are the most active area of metabolic research right now. This collection covers every generation of incretin compound, from single-receptor GLP-1 agonists like semaglutide to dual and triple agonists and the amylin analogue cagrilintide. Every vial is lyophilized, vacuum-sealed and tested to over 99% purity by HPLC-MS.

Single, dual and triple agonists
Semaglutide targets the GLP-1 receptor alone. Tirzepatide adds GIP. Retatrutide covers GIP, GLP-1 and glucagon in one molecule. Mazdutide and survodutide pair GLP-1 with glucagon, and cagrilintide works through amylin receptors, which is why it is studied alongside semaglutide as CagriSema.

Picking a strength
Small vials suit pilot work. Larger vials cost less per milligram and keep a long project on a single lot. Most products also come in multi-vial packs that save up to 30%.

In this collection: Semaglutide 2mg, Semaglutide 5mg, Semaglutide 10mg, Tirzepatide 5mg, Tirzepatide 10mg, Tirzepatide 30mg, Mazdutide 6mg, Retatrutide 15mg, Semaglutide 12.5mg, Cagrilintide 5mg, Retatrutide 5mg, Survodutide 5mg, Cagrilintide Semaglutide Blend 3mg/3mg, Semaglutide 20mg, Tirzepatide 50mg, Cagrilintide Semaglutide Blend 10mg/10mg, Retatrutide 35mg, Cagrilintide 10mg, Tirzepatide 60mg, Retatrutide 10mg, Retatrutide 60mg.

What are GLP-1 peptides?
Synthetic analogues of glucagon-like peptide-1, a gut hormone involved in insulin release, appetite and gastric emptying, or compounds that act on the same pathway.

Which GLP-1 peptide has the most research behind it?
Semaglutide, followed by tirzepatide. Retatrutide is the most studied triple agonist.

All products are sold for laboratory research use only. Not for human or veterinary use.